Sign In
Media release
From:
Attachments
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Drug shows promise for reducing fatigue in long-COVID patients
Publicly released:
International
A drug designed to help long-COVID patients suffering from persistent fatigue has shown promise in a randomised controlled trial, according to an international study presented at the European Congress of Clinical Microbiology & Infectious Diseases. The team trialled the drug, AXA1125, against a placebo in a group of 41 people with long-COVID fatigue. After a month, the researchers said the participants showed no difference when tested on their walking and muscle recovery, however the AXA1125 group scored better on a questionnaire about their fatigue compared to the placebo group.
Media Contact/s 
Contact details are only visible to registered journalists.
Share this page
More News
Immune system dysfunction may explain why chronic illness and depression often go hand in hand
Australia; VIC
The University of Melbourne,La Trobe University
Nature Mental Health
Combination immunotherapy shows improved efficacy and survival rates in rare cancer study
Australia; New Zealand; NSW; VIC; QLD; SA; WA; TAS
La Trobe University,Olivia Newton-John Cancer Research Institute...
JAMA Oncology
Do e-cigarettes compromise children's human rights?
Australia; International; ACT
The Australian National University,University of Bath...
The BMJ